36 is the current PE of CSL ( biggest biotech on asx ) , and just happens to be same PE for reoccurring royalties for Nuren. Asx bio startup ( like botanix ) that recieved fda clearance recently.
It could just be a fluke they are both 36, but what a coincidence. I only looked at those two. CSL for what investors value a long term solid , slow growth medical vs short term startup ( Nuren ) with first product just in market, so 36 PE is what the evidence points towards in my opinion.
The big unknown, is the E ?
Currently priced at around 3000 patients for 1 year, or 36,000 patients for a 1 off 1 month buy.
- Forums
- ASX - By Stock
- BOT
- Where will we be in 12 months time?
Where will we be in 12 months time?, page-137
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $752.8M |
Open | High | Low | Value | Volume |
41.0¢ | 43.5¢ | 41.0¢ | $2.989M | 7.071M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 408524 | 41.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 359035 | 0.415 |
6 | 383895 | 0.410 |
8 | 528535 | 0.405 |
12 | 590183 | 0.400 |
7 | 403387 | 0.395 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 30000 | 1 |
0.425 | 136193 | 1 |
0.430 | 190093 | 5 |
0.435 | 26426 | 1 |
0.440 | 250447 | 8 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |